1. Home
  2. ABOS

as 05-24-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.

Founded: 1996 Country:
United States
United States
Employees: N/A City: CHARLOTTESVILLE
Market Cap: 228.9M IPO Year: 2021
Target Price: $12.60 AVG Volume (30 days): 298.0K
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.06 EPS Growth: N/A
52 Week Low/High: $1.81 - $11.31 Next Earning Date: 05-14-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks:

Stock Insider Trading Activity of Acumen Pharmaceuticals Inc. (ABOS)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Meisner Derek M ABOS Chief Legal Officer & Corp Sec Jan 19 '24 Sell $3.48 8,933 $31,048.43 108,867 SEC Form 4
OConnell Daniel Joseph ABOS President and CEO Jan 19 '24 Sell $3.47 15,200 $52,753.12 502,485 SEC Form 4
Barton Russell ABOS Chief Operating Officer Jan 18 '24 Sell $3.73 2,833 $10,555.19 96,867 SEC Form 4